Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.

Vaupel A, Bold G, De Pover A, Stachyra-Valat T, Lisztwan JH, Kallen J, Masuya K, Furet P.

Bioorg Med Chem Lett. 2014 May 1;24(9):2110-4. doi: 10.1016/j.bmcl.2014.03.039. Epub 2014 Mar 22. Erratum in: Bioorg Med Chem Lett. 2015 Mar 15;25(6):1356. Hergovich-Lisztwan, Joanna [corrected to Lisztwan, Joanna Hergovich].

PMID:
24704029
2.

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR.

Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7.

3.

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, Marque F, Régnier CH, De Pover A, Ryckelynck H, Bhagwat N, Koppikar P, Goel A, Wyder L, Tavares G, Baffert F, Pissot-Soldermann C, Manley PW, Gaul C, Voshol H, Levine RL, Sellers WR, Hofmann F, Radimerski T.

Cancer Discov. 2012 Jun;2(6):512-523. doi: 10.1158/2159-8290.CD-11-0324. Epub 2012 May 3.

4.

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.

Furet P, Chène P, De Pover A, Valat TS, Lisztwan JH, Kallen J, Masuya K.

Bioorg Med Chem Lett. 2012 May 15;22(10):3498-502. doi: 10.1016/j.bmcl.2012.03.083. Epub 2012 Mar 30.

PMID:
22507962
5.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

6.

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.

Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21.

7.

Leveraging the contribution of thermodynamics in drug discovery with the help of fluorescence-based thermal shift assays.

Hau JC, Fontana P, Zimmermann C, De Pover A, Erdmann D, Chène P.

J Biomol Screen. 2011 Jun;16(5):552-6. doi: 10.1177/1087057111399573. Epub 2011 Mar 25.

PMID:
21441415
8.

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.

Baffert F, Régnier CH, De Pover A, Pissot-Soldermann C, Tavares GA, Blasco F, Brueggen J, Chène P, Drueckes P, Erdmann D, Furet P, Gerspacher M, Lang M, Ledieu D, Nolan L, Ruetz S, Trappe J, Vangrevelinghe E, Wartmann M, Wyder L, Hofmann F, Radimerski T.

Mol Cancer Ther. 2010 Jul;9(7):1945-55. doi: 10.1158/1535-7163.MCT-10-0053. Epub 2010 Jun 29.

10.

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Gerspacher M, Furet P, Pissot-Soldermann C, Gaul C, Holzer P, Vangrevelinghe E, Lang M, Erdmann D, Radimerski T, Regnier CH, Chene P, De Pover A, Hofmann F, Baffert F, Buhl T, Aichholz R, Blasco F, Endres R, Trappe J, Drueckes P.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1724-7. doi: 10.1016/j.bmcl.2010.01.069. Epub 2010 Jan 21.

PMID:
20138510
11.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.

Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7.

12.

Effects of intestinal fatty acid-binding protein overexpression on fatty acid metabolism in Caco-2 cells.

Darimont C, Gradoux N, Persohn E, Cumin F, De Pover A.

J Lipid Res. 2000 Jan;41(1):84-92.

13.

Properties of the human long and short isoforms of the uncoupling protein-3 expressed in yeast cells.

Hinz W, Grüninger S, De Pover A, Chiesi M.

FEBS Lett. 1999 Dec 3;462(3):411-5.

14.

Epidermal growth factor regulates fatty acid uptake and metabolism in Caco-2 cells.

Darimont C, Gradoux N, de Pover A.

Am J Physiol. 1999 Mar;276(3):G606-12. doi: 10.1152/ajpgi.1999.276.3.G606.

PMID:
10070036
15.

Differential regulation of intestinal and liver fatty acid-binding proteins in human intestinal cell line (Caco-2): role of collagen.

Darimont C, Gradoux N, Cumin F, Baum HP, De Pover A.

Exp Cell Res. 1998 Nov 1;244(2):441-7.

PMID:
9806794
16.

Inhibition of lipid absorption as an approach to the treatment of obesity.

Thomson AB, De Pover A, Keelan M, Jarocka-Cyrta E, Clandinin MT.

Methods Enzymol. 1997;286:3-44. Review.

PMID:
9309643
17.

Characterisation of Na/K-ATPase, its isoforms, and the inotropic response to ouabain in isolated failing human hearts.

Shamraj OI, Grupp IL, Grupp G, Melvin D, Gradoux N, Kremers W, Lingrel JB, De Pover A.

Cardiovasc Res. 1993 Dec;27(12):2229-37.

PMID:
8313433
18.

Na,K-ATPase isozymes in rat tissues: differential sensitivities to sodium, vanadate and dihydroouabain.

Feige G, Leutert T, De Pover A.

Prog Clin Biol Res. 1988;268B:377-84. No abstract available.

PMID:
2851817
19.

Endogenous digitalis-like factor and inotropic receptor sites in rat heart.

De Pover A.

Eur J Pharmacol. 1984 Apr 6;99(4):365-6. No abstract available.

PMID:
6329792
20.

Influence of 16 beta formylation on Na, K-ATPase inhibition by cardiac glycosides.

De Pover A, Godfraind T.

Naunyn Schmiedebergs Arch Pharmacol. 1982 Nov;321(2):135-9.

PMID:
6296702
21.

Dihydroouabain is an antagonist of ouabain inotropic action.

Godfraind T, Ghysel-Burton J, De Pover A.

Nature. 1982 Oct 28;299(5886):824-6.

PMID:
6290892
22.

Pharmacological inhibition of the actions of low concentrations of ouabain in guinea-pig isolated atria.

Godfraind T, Ghysel-Burton J, De Pover A.

Arch Int Pharmacodyn Ther. 1982 Jul;258(1):168-70. No abstract available.

PMID:
7138142
23.

Cardiodigin: endogenous digitalis-like material from mammalian heart.

Godfraind T, De Pover A, Castaneda Hernandez G, Fagoo M.

Arch Int Pharmacodyn Ther. 1982 Jul;258(1):165-7. No abstract available.

PMID:
7138141
24.

Water versus acetone-HCl extraction of digitalis-like factor from guinea-pig heart.

De Pover A, Castañeda-Hernández G, Godfraind T.

Biochem Pharmacol. 1982 Jan 15;31(2):267-71. No abstract available.

PMID:
6277341
25.

Identification with potassium and vanadate of two classes of specific ouabain binding sites in a (Na+ + K+) ATPase preparation from the guinea-pig heart.

Godfraind T, De Pover A, Lutete DN.

Biochem Pharmacol. 1980 Apr 15;29(8):1195-9. No abstract available.

PMID:
6248074
26.

Interaction of ouabain with (Na+ + K+)ATPase from human heart and from guinea-pig heart.

De Pover A, Godfraind T.

Biochem Pharmacol. 1979 Oct 15;28(20):3051-6. No abstract available.

PMID:
229866
27.

Parameters of [3H]-ouabain binding to human heart (Na+ + K+)-ATPase [proceedings].

de Pover A, Godfraind T.

Br J Pharmacol. 1979 Jul;66(3):471P-472P. No abstract available.

28.

The inhibition of human heart (Na + K) ATPase by semisynthetic digitalis glycosides.

Lutete NT, Noel F, de Pover A, Godfraind T.

Arch Int Pharmacodyn Ther. 1977 May;227(1):166-7. No abstract available.

PMID:
143253
29.

Influence of pH and sodium on the inhibition of guinea-pig heart (Na+ + K+)-ATPase by calcium.

Godfraind T, De Pover A, Verbeke N.

Biochim Biophys Acta. 1977 Mar 15;481(1):202-11.

PMID:
14690
30.
31.

Sensitivity to cardiac glycosides of (Na + K) ATPase prepared from human heart, guinea-pig heart and guinea-pig brain.

De Pover A, Godfraind T.

Arch Int Pharmacodyn Ther. 1976 Jun;221(2):339-41. No abstract available.

PMID:
134678
32.

[Pharmacology of (Na+ + K+)-ATPase in the human heart muscle].

Godfraind T, De Pover A.

Bull Mem Acad R Med Belg. 1976;131(6-8):295-315. French. No abstract available.

PMID:
140717
33.

Proceedings: [Influence of Na and K on inhibition of (Na + K)-ATPase of guinea pig heart by digoxin or calcium].

Godfraind T, De Pover A.

Arch Int Physiol Biochim. 1975 Aug;83(3):599-601. French. No abstract available.

PMID:
54140
34.

The inhibition of the Na-K-ATPase of guinea-pig heart microsomes by cardiac glycosides.

Godfraind T, De Pover A.

Arch Int Pharmacodyn Ther. 1973 Jan;201(1):197-200. No abstract available.

PMID:
4268671

Supplemental Content

Loading ...
Support Center